Aiming for a Higher Cure Rate: Strategies for Salvage Treatment at Relapse in HL

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: February 17, 2016
Expiration Date: February 17, 2017

Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

To mark ASCO’s 50th anniversary, the cancer community was called upon to help select the five most pivotal clinical cancer research advances since the organization was established, and the development of curative systemic treatment of Hodgkin lymphoma ranked first among them. The high expectation of cure greater than 80% with initial therapy, even for advanced disease, belies some well-recognized limitations which have remained. Among these, not all patients are cured; 10% of patients will not achieve a complete remission and 20–30% of patients who initially responded will experience a relapse. After the passing of several decades since the introduction of curative conventional cytoxic treatments where a variety of ways of combining these treatments with or without radiotherapy yielded no significant improvement to patient outcomes, progress is once again being made with the application of functional imaging with (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) to make an early judgment of the success of treatment and the introduction of some highly active new agents such as antibody-drug conjugates. Join Robert Chen, MD, of the Department of Hematology/HCT at the City of Hope Medical Center for a discussion regarding the latest strategies for salvage therapy at relapse in Hodgkin lymphoma.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in Hodgkin lymphoma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Outline current standards for salvage therapies at relapse after first-line therapy, prior to high-dose marrow-ablative chemotherapy and autologous SCT
  • Identify the rationale behind increasing the fraction of PET-negative metabolic CR patients prior to ASCT


Aiming for a Higher Cure Rate: Strategies for Salvage Treatment at Relapse in HL – Robert W. Chen, MD

Instructions for Participation and Credit

This activity is eligible for credit through February 17, 2017. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Robert W. Chen, MD
Assistant Professor of Medicine
Department of Hematology
& Hematopoietic Cell Transplantation
City of Hope
Duarte, California

Dr. Robert Chen received his medical degree from Northwestern University Medical School Chicago, Illinois. He completed his internal medicine residency at the University of Colorado Health Sciences Center in Denver, and his hematology/oncology fellowship at the University of Colorado Cancer Center, Aurora, Colorado. Dr. Chen is an assistant professor and staff physician in the Department of Hematology and Hematopoietic Cell Transplantation, City of Hope (COH) in Duarte, California

At COH, Dr. Chen is also the co-leader of the lymphoma disease and early phase therapeutic disease teams; associate director, phase I/II trials in malignant hematology; and associate director of phase I/II trials in malignant hematology. In addition, he is an NCCN Hodgkin lymphoma panel member, on the SWOG lymphoma working group, and is associate chair, Cedar Park Regional Medical Center (CPRMC). Dr. Chen holds memberships in the American Society of Hematology, American Society of Clinical Oncology, American Association for Cancer Research, and the Rocky Mountain Oncology Society (Colorado), among others. He is a reviewer for the Journal of Clinical Oncology, Blood, Biology of Bone and Marrow Transplantation, Oncogene, Plos, Leukemia Research, Lymphoma and Leukemia, Clinical Lymphoma and Myeloma, as well as the American Society of Hematology.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-16-071-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Robert Chen has received honoraria related to speakers’ bureau activities from Seattle Genetics, Inc., Takeda Oncology, and Genentech, Inc., as well as consultant fees from Merck & Co., Inc. and Seattle Genetics. He has received grant support related to research activities from Merck, Pharmacyclics, Inc., Seattle Genetics, and Takeda Oncology.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Chen has indicated that he does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Chen has indicated that he does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US. Dr. Robert Chen has disclosed relevant financial relationships.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Takeda Oncology.

©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

MediCom Worldwide, Inc. would like to recognize and thank Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics for their educational support. To better serve the needs of our audience, is now

©2019 MediCom Worldwide, Inc. All rights reserved